Biologia Futura: Emerging antigen-specific therapies for autoimmune diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review discussing therapeutic mechanisms without primary empirical data or systematic review methodology.
PubMed 34554499 · doi:10.1007/s42977-021-00074-4
What was done
This narrative review outlines the mechanistic rationale and emerging strategies for antigen-specific therapies in autoimmune diseases. It describes approaches designed to selectively restore immune tolerance, including autoantigenic peptides bound to nanoparticles, in vitro manipulated autologous tolerogenic antigen-presenting cells (APCs), autoantigen-specific regulatory T (Treg) cells, and chimeric autoantibody receptor T cells targeting autoreactive B cells.
What was found
The abstract provides no quantitative experimental results or clinical trial outcome metrics. It describes the mechanisms and theoretical frameworks of emerging targeted immunotherapies intended to suppress autoreactive T or B cells while preserving general protective immunity against pathogens.
Why it matters
Current autoimmune therapies rely heavily on broad immunosuppression, which increases infection risks; developing selective, autoantigen-specific approaches could resolve underlying autoimmunity while maintaining normal immune defense.
Limits
The abstract reports no primary clinical or preclinical experimental data, sample sizes, or quantitative outcome measures. It functions as a conceptual narrative review, so real-world clinical efficacy, safety, delivery challenges, and manufacturing hurdles are not quantitatively assessed.
Cited by
- supports Autoimmune diseases result when self-reactive T cells escape thymic negative selection and secondary peripheral tolerance mechanisms fail, leading to immune attack on specific host tissues like joint targets in rheumatoid arthritis, pancreatic insulin-producing cells in type 1 diabetes, or myelin in multiple sclerosis.